Clinical Trials

40 enrolled

Lymphoma, Follicular

NCT05798156 2026-04-08

R-Pola-Glo

125 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06108232 2026-04-07

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

33 enrolled

Lymphoma, Follicular, Neoplasms

NCT04722172 2026-04-06

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02537613 2026-04-01

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

54 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06192888 2026-03-27

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

39 enrolled

Lymphoma, Mantle-Cell

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

40 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

47 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02629809 2026-03-06

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

81 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05650723 2026-02-25

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198026 2026-02-19

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

30 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT02846623 2026-02-17

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Other hematologic neoplasm

30 enrolled

Leukemia, Leukemia, Hairy Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Phase 1/2 Active not recruiting

87 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04843904 2026-01-07

SAVE

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04447768 2025-10-14

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

100 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

22 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03872180 2025-08-06

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

23 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT04515238 2025-06-10

CLL2-BZAG

42 enrolled

Leukemia, B-Cell

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT03322865 2025-04-04

Obinutuzumab in Marginal Zone Lymphoma

56 enrolled

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT04962126 2025-03-21

FLUORO

15 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular

NCT04608318 2024-12-31

CLL17

897 enrolled

Leukemia, B-Cell

NCT06547944 2024-08-09

ZGR in TN CLL

30 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03980171 2024-07-29

LEVERAGE

50 enrolled

Lymphoma, Follicular

NCT05387616 2024-03-12

Alternative-C

98 enrolled